首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:European urology oncology

缩写:

ISSN:N/A

e-ISSN:2588-9311

IF/分区:9.3/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引1249
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Claire Forde,Derek H K Lim,Yousef Alwan et al. Claire Forde et al.
Background: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumour predisposition syndrome characterised by predisposition to cutaneous and uterine leiomyomata and renal cell carcinoma (RCC). ...
Alberto Martini,Nicola Fossati,R Jeffrey Karnes et al. Alberto Martini et al.
Intermediate clinical endpoints (ICEs) might aid in trial design and potentially expedite study results. However, little is known about the most informative ICE for patients receiving salvage radiation therapy (sRT) after radical prostatect...
Jeffrey Graham,Amishi Y Shah,J Connor Wells et al. Jeffrey Graham et al.
Background: Immuno-oncology (IO) therapies have changed the treatment standards of metastatic renal cell carcinoma (mRCC). However, the effectiveness of targeted therapy following discontinuation of IO therapy in real-wor...
Renzo G DiNatale,Wanling Xie,Maria F Becerra et al. Renzo G DiNatale et al.
Background: One of the main challenges in the management of renal cell carcinoma (RCC) is risk-stratifying patients who present with metastatic disease. Tumor size is an important predictor of survival in the localized se...
Ivo G Schoots,Anwar R Padhani,Olivier Rouvière et al. Ivo G Schoots et al.
Background: The use of a magnetic resonance imaging (MRI)-directed diagnostic pathway in men at first prostate cancer work-up has been introduced within European prostate cancer guidelines. Differences in MRI-directed pat...
Denis Maillet,Nathalie Allioli,Julien Peron et al. Denis Maillet et al.
Background: In metastatic castration-resistant prostate cancer (mCRPC), androgen receptor splice variant 7 (AR-V7) expression is associated with a low response to androgen receptor signaling (ARS) inhibitors such as abira...